02335 麥科醫藥－Ｂ
MICOT PHARMA-B
MICOT PHARMA-B
| Register Close | 2026/06/18 IPO Closing in 3 Days |
| Listing Date | 2026/06/24 |
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Shaanxi Micot Pharmaceutical Technology Co. is a biotechnology company specializing in the discovery, development and commercialization of bi-/multi-specific peptide drugs for the treatment of metabolic diseases as well as cardiovascular and cerebrovascular diseases. The Group has self-developed a product pipeline of one Core Product and other six product candidates.
--
The Group’s Core Product MT1013 is a self-developed, Phase III-stage, dual-targeting receptor agonist polypeptide that simultaneously targets the CaSR and the OGP receptor, primarily designed for the treatment of Chronic Kidney Disease-Secondary Hyperparathyroidism (“CKD-SHPT”) with potential for expansion into additional indications such as Chronic Kidney Disease-Mineral and Bone Disorder (“CKD-MBD”) with osteoporosis and CKD-SHPT not on Dialysis.
--
As of June 7, 2026, the Group owned 10 granted patents in the PRC, three granted patents in Hong Kong, 23 granted patents overseas, and three patent applications in the PRC, three patent applications in Hong Kong, 9 patent applications overseas and one PCT patent application.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 200 |
GLOBAL OFFERING
| No. of Offer Shares | 58.05M H shares |
| No. of International Offer Shares | 52.25M H shares |
| No. of HK Offer Shares | 5.81M H shares |
| Offer Price | $18.20 - $21.00 |
| Stock Code | 2335 |
| Sponsor(s) | CCB International Capital Limited, China Merchants Securities (HK) Co., Limited |
| Underwriter(s) | CCB International Capital Limited, China Merchants Securities (HK) Co., Limited, Jakota Securities Group Limited, Ruibang Securities Limited, Sinolink Securities (Hong Kong) Company Limited, Skyvast Securities Limited, Somerley Capital Limited, Tiger Brokers (HK) Global Limited, uSmart Securities Limited, Webull Securities Limited, Zhongtai International Securities Limited, ZMF Asset Management Limited |
TIME TABLE
| Application Period | Jun 15 (Mon) - noon, Jun 18 (Thu) |
| Price Determination Date | -- |
| Result Announcement Date | On or before Jun 23 (Tue) |
| Result Announcement Date | On or before Jun 23 (Tue) |
| Result Announcement Date | On or before Jun 24 (Wed) |
| Dealings in Shares commence on | Jun 24, 2026. (Wed) |
Reallocation of Shares Offered
Sales Statistics (HKD)
| Offer Price | $18.20 - $21.00 |
| Capitalization | 6.04B - 6.97B |
| NAV / share ($) | $-0.37 - $0.12 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 19.6, the net proceeds raised would be HKD 1.07B, of which |
| 39.1% : Used for ongoing and planned clinical trials and planned commercial launch of Core Product |
| 36.3% : Ongoing and planned clinical trials and planned commercial launch of our Key Products |
| 14.6% : R&D of other product candidates and technology platforms |
| 10% : Working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).